Anish John - Aug 15, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Chief Financial Officer
Signature
/s/ Anish John
Stock symbol
OCX
Transactions as of
Aug 15, 2022
Transactions value $
$0
Form type
4
Date filed
8/17/2022, 08:19 PM
Previous filing
Jun 13, 2022
Next filing
Jan 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Award $0 +150K $0.00 150K Aug 15, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +100K $0.00 100K Aug 15, 2022 Common Stock 100K $0.97 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units shall vest on January 1, 2024 based on the achievement of a pre-determined financial objective related to the Issuer's available cash.
F2 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.